Literature DB >> 7689594

Staphylococcal enterotoxin enhances the activation of rat encephalitogenic T cells by myelin basic protein.

D Sun1.   

Abstract

It is generally believed that the activation of autoreactive T cells is an essential step in the pathogenesis of autoimmune diseases; however, autologous antigens are often weak immunogens and their detectable levels in vivo are much lower than required for T-cell activation. In experimental autoimmune encephalomyelitis, encephalitogenic T cells specific for myelin basic protein (MBP) react weakly to autologous rat myelin basic protein (RBP) but strongly to guinea pig-derived basic protein, even though both ligands possess the essential epitope (MBP(68-88)). Here we demonstrate that RBP is converted to a strong immunogen in the presence of a small dose of bacterial superantigen, staphylococcal enterotoxin E (SEE). The enhancing effect of SEE on the rat protein was apparent with all encephalitogenic T-cell lines examined in this study, including those not responding to RBP alone. It depended, moreover, on the simultaneous presence of RBP and SEE; delaying the addition of SEE for 8-12 h greatly decreased the potency of RBP. None of a series of major cytokines was able to replace SEE as an enhancer. Our results indicate that two T ligands, one a bacterial superantigen, can interact to enhance the activation of autoreactive T cells. This observation has implications for the involvement of bacterial and viral infections in the pathogenesis of multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7689594     DOI: 10.1016/0165-5728(93)90227-p

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  2 in total

1.  Letter fraud.

Authors:  N Craft
Journal:  BMJ       Date:  1995-08-26

2.  Minimally activated CD8 autoreactive T cells specific for IRBP express a high level of Foxp3 and are functionally suppressive.

Authors:  Yong Peng; Hui Shao; Yan Ke; Ping Zhang; Gencheng Han; Henry J Kaplan; Deming Sun
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-05       Impact factor: 4.799

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.